PE20050466A1 - HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE 9 (PDE9) - Google Patents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE 9 (PDE9)

Info

Publication number
PE20050466A1
PE20050466A1 PE2004000413A PE2004000413A PE20050466A1 PE 20050466 A1 PE20050466 A1 PE 20050466A1 PE 2004000413 A PE2004000413 A PE 2004000413A PE 2004000413 A PE2004000413 A PE 2004000413A PE 20050466 A1 PE20050466 A1 PE 20050466A1
Authority
PE
Peru
Prior art keywords
pyrimidin
pyrazole
dihydro
oxo
type
Prior art date
Application number
PE2004000413A
Other languages
Spanish (es)
Inventor
Michael Scott Visser
Andrew Simon Bell
Michael John Palmer
Michael Paul Deninno
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20050466A1 publication Critical patent/PE20050466A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE LA FORMULA (I), EN DONDE A ES UN RADICAL DE FORMULA (a), (d), (g), ENTRE OTROS; P ES CICLOALQUILO(C3-C5), HETEROCICLOALQUILO(C3-C8), ARILO O HETEROARILO, OPCIONALMENTE SUSTITUIDOS; J ES O, S, -N(R15)-, -N(R15)CO-, -CON(R15)-, ENTRE OTROS; x ES DE 0 A 6; R10 ES -CO2H, -CONR30R31, -NR30R31, O -N(R15)SO2R40; R1 Y R2 SON, INDEPENDIENTEMENTE, H O ALQUILO(C1-C3); R3 ES ALQUILO(C1-C8), CICLOALQUILO(C3-C8), HETEROCICLOALQUIL(C3-C8), METILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 1-{[2-(3-ISOPROPIL-7-OXO-6,7-DIHIDRO-1H-PIRAZOLO[4,3-d]PIRIMIDIN-5-ILMETIL)FENOXI]ACETIL}PIRROLIDINA-2-CARBOXILICO, N-[(1R,2S)-2-(3-ISOPROPIL-7-OXO-6,7-DIHIDRO-1H-PIRAZOLO[4,3-d]PIRIMIDIN-5-ILMETIL)CICLOHEXIL-1-IL]2-PIRROLIDIN-1-IL ACETAMIDA, ESTER METILICO DEL ACIDO 1-{[(1R,2S)-2-(3-ISOPROPIL-7-OXO-6,7-DIHIDRO-1H-PIRAZOLO[4,3-d]PIRIMIDIN-5-ILMETIL)CICLOHEX-1-ILCARBAMOIL]METIL}PIRROLIDINA-2(S)-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE FOSFODIESTERASA TIPO 9 ESPECIFICOS DEL MONOFOSFATO CICLICO DE GUANOSINA Y SON UTILES EN EL TRATAMIENTO DE DIABETES TIPO 1 Y TIPO 2, HIPERGLUCEMIA, DISLIPIDEMIA, TOLERANIA A LA GLUCOSA ALTERADA, SINDROME METABOLICO Y/O ENFERMEDAD CARDIOVASCULARREFERS TO COMPOUNDS DERIVED FROM FORMULA (I), WHERE A IS A RADICAL OF FORMULA (a), (d), (g), AMONG OTHERS; P IS CYCLOALKYL (C3-C5), HETEROCICLOALKYL (C3-C8), ARYL OR HETEROARYL, OPTIONALLY SUBSTITUTED; J IS O, S, -N (R15) -, -N (R15) CO-, -CON (R15) -, AMONG OTHERS; x IS FROM 0 TO 6; R10 IS -CO2H, -CONR30R31, -NR30R31, O -N (R15) SO2R40; R1 AND R2 ARE, INDEPENDENTLY, H OR ALKYL (C1-C3); R3 IS ALKYL (C1-C8), CYCLOALKYL (C3-C8), HETEROCICLOALKYL (C3-C8), METHYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 1 - {[2- (3-ISOPROPYL-7-OXO-6,7-DIHYDRO-1H-PYRAZOLE [4,3-d] PYRIMIDIN-5-ILMETHYL) PHENOXY] ACETYL} PYRROLIDINE-2- CARBOXYL, N - [(1R, 2S) -2- (3-ISOPROPYL-7-OXO-6,7-DIHYDRO-1H-PYRAZOLE [4,3-d] PYRIMIDIN-5-ILMETHYL) CYCLOHEXYL-1-IL] 2-PYRROLIDIN-1-IL ACETAMIDE, ACID METHYL ESTER 1 - {[(1R, 2S) -2- (3-ISOPROPYL-7-OXO-6,7-DIHYDRO-1H-PYRAZOLE [4,3-d] PYRIMIDIN-5-ILMETIL) CYCLOHEX-1-ILCARBAMOIL] METHYL} PYRROLIDINE-2 (S) -CARBOXYL, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE SPECIFIC INHIBITORS OF TYPE 9 PHOSPHODIESTERASE OF CYCLIC GUANOSINE MONOPHOSPHATE AND ARE USEFUL IN THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES, HYPERGLYCAEMIA, DYSLIPIDEMIA, TOLERANIA A LA GLYCEDULATE / ALTERABLY GLYCEDULATE SYNDROME

PE2004000413A 2003-04-30 2004-04-27 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE 9 (PDE9) PE20050466A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46663903P 2003-04-30 2003-04-30

Publications (1)

Publication Number Publication Date
PE20050466A1 true PE20050466A1 (en) 2005-06-18

Family

ID=33551403

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000413A PE20050466A1 (en) 2003-04-30 2004-04-27 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE 9 (PDE9)

Country Status (8)

Country Link
AR (1) AR044119A1 (en)
CL (1) CL2004000901A1 (en)
GT (1) GT200400086A (en)
NL (1) NL1026091C2 (en)
PA (1) PA8601601A1 (en)
PE (1) PE20050466A1 (en)
TW (1) TW200503714A (en)
UY (1) UY28291A1 (en)

Also Published As

Publication number Publication date
UY28291A1 (en) 2004-11-30
NL1026091A1 (en) 2004-11-02
GT200400086A (en) 2005-01-11
CL2004000901A1 (en) 2005-03-18
NL1026091C2 (en) 2005-05-26
AR044119A1 (en) 2005-08-24
TW200503714A (en) 2005-02-01
PA8601601A1 (en) 2005-02-04

Similar Documents

Publication Publication Date Title
PE20071061A1 (en) CARBONYL DERIVATIVES AS PEPTIDYL-DEFORMYLASE INHIBITORS (PDF)
PE20080318A1 (en) DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS
PE20080552A1 (en) DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
PE20091712A1 (en) DERIVATIVES OF AZETIDINE AND CYCLOBUTANE AS JAK INHIBITORS
PE20060602A1 (en) HETEROARYL ACIL PYRROLIDINE DERIVATIVES AS INHIBITORS OF HEPATITIS C VIRUS (HCV)
PE20061353A1 (en) SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS
PE20080404A1 (en) BENZYL-AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS
PE20050948A1 (en) CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
PE20051061A1 (en) 5,7-DIAMINOPYRAZOLE [4,3-d] PYRIMIDINES
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20090964A1 (en) PYROLO [2,3-D] PYRIMIDINE DERIVATIVES AS PROTEIN KINASE B INHIBITORS
RU2009135621A (en) QUINOLINE DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES
AR036114A1 (en) TETRAHYDROIMIDAZOL [1,2-A] PIRAZINS AND TETRAHYDROTRIAZOL [4,3-A] PIRAZINS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE USEFUL FOR THE TREATMENT OR PREVENTION OF DIABETES
PE20080951A1 (en) DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS
PE20070179A1 (en) PURINE DERIVATIVES AS AGONISTS OF THE ADENOSINE A2 RECEPTOR
PE20130239A1 (en) HETEROARYL-ARYL-UREAS COMPOUNDS AS KINASE INHIBITORS
NO20050418L (en) Condensed pyridines and pyrimidines with TIE2 (TEK) activity
PE20090326A1 (en) HETEROCYCLES COMPOUNDS AS ERK INHIBITORS
PE20100144A1 (en) CHEMICAL COMPOUNDS 293
PE20081354A1 (en) AZAINDOLYL COMPOUNDS AS MEK INHIBITORS
PE20090880A1 (en) HETEROCYCLIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
EA201170780A1 (en) URATIC CYCLOPROPYLNUCLEOTIDES
PE20070212A1 (en) 1,4-DIHYDROPYRIDINE-CONDENSED HETEROCYCLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
PE20050078A1 (en) PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS

Legal Events

Date Code Title Description
FC Refusal